Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

33.65
-0.3282-0.97%
Post-market: 33.650.00000.00%16:10 EDT
Volume:3K
Turnover:102.82K
Market Cap:13.46M
PE:- -
High:33.77
Open:33.77
Low:33.14
Close:33.98
52wk High:34.98
52wk Low:27.25
Shares:400.00K
Float Shares:400.00K
Volume Ratio:1.96
T/O Rate:0.77%
Dividend:0.08
Dividend Rate:0.24%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Cognizant announces five-year extension of its work with Gilead Sciences

TIPRANKS
·
Oct 06

Cognizant - to Support Gilead's Devops and AI Tools Across Selected Technology Programs

THOMSON REUTERS
·
Oct 06

Cognizant Expands AI-Enabled Devops Capabilities for Gilead Sciences

THOMSON REUTERS
·
Oct 06

Entera Bio Appoints Ex-Gilead Executive Laura Hamill to Board of Directors

Reuters
·
Oct 06

Tech Coast Angels Reports Profitable Atraverse Medical Exit After Johnson & Johnson Acquisition, Citing 70%+ IRR

Reuters
·
Oct 06

L'Oreal Explores Unloading Chemical-Related Liabilities, WSJ Reports

Reuters
·
Oct 06

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

Edwards Lifesciences Corp. Stock Underperforms Monday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Oct 06

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

Moderna Inc. Stock Rises 6.9%, Outperforms Peers

Dow Jones
·
Oct 06

IntegraGen Faces Judicial Liquidation as Court Weighs Takeover Bids

TIPRANKS
·
Oct 06

Merck & Co Inc Stock (MRK) Moved Down by 3.04% on Oct 5: What Investors Need To Know

TradingKey
·
Oct 05

Evercore ISI Adjusts Price Target on Edwards Lifesciences to $102 From $100, Keeps Outperform Rating

MT Newswires Live
·
Oct 05

JPMorgan Adjusts Price Target on Merck & Co. to $165 From $150, Maintains Overweight Rating

MT Newswires Live
·
Oct 05

Nurix, Gilead Extend Research Term for Oncology Program by Two Years for $10 Million Fee

Reuters
·
Oct 05

Nurix Extends Gilead Collaboration for Oncology Program

Reuters
·
Oct 05

CSPC Pharma to Unveil Eight New Clinical Trial Advances at 2026 ESMO Congress

Stock News
·
Oct 05

Nurix - Eligible for up to $1.30 Bln in Total Payments as of May 31, 2026

THOMSON REUTERS
·
Oct 05

Nurix - Eligible for Mid-Single-Digit to Low-Teens Percentage Tiered Royalties

THOMSON REUTERS
·
Oct 05

Nurix - to Receive $10 Mln Research Term Extension Fee

THOMSON REUTERS
·
Oct 05